646 related articles for article (PubMed ID: 30149876)
1. Modeling Tumor Immunology and Immunotherapy in Mice.
Buqué A; Galluzzi L
Trends Cancer; 2018 Sep; 4(9):599-601. PubMed ID: 30149876
[TBL] [Abstract][Full Text] [Related]
2. Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice.
Choi Y; Lee S; Kim K; Kim SH; Chung YJ; Lee C
Exp Mol Med; 2018 Aug; 50(8):1-9. PubMed ID: 30089794
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216
[TBL] [Abstract][Full Text] [Related]
4. Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes.
Marín-Jiménez JA; Capasso A; Lewis MS; Bagby SM; Hartman SJ; Shulman J; Navarro NM; Yu H; Rivard CJ; Wang X; Barkow JC; Geng D; Kar A; Yingst A; Tufa DM; Dolan JT; Blatchford PJ; Freed BM; Torres RM; Davila E; Slansky JE; Pelanda R; Eckhardt SG; Messersmith WA; Diamond JR; Lieu CH; Verneris MR; Wang JH; Kiseljak-Vassiliades K; Pitts TM; Lang J
Front Immunol; 2021; 12():607282. PubMed ID: 33854497
[TBL] [Abstract][Full Text] [Related]
5. Patient-Derived Xenograft Models for Translational Prostate Cancer Research and Drug Development.
Philp LK
Methods Mol Biol; 2024; 2806():153-185. PubMed ID: 38676802
[TBL] [Abstract][Full Text] [Related]
6. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
Kerbel RS; Shaked Y
Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
[TBL] [Abstract][Full Text] [Related]
7. Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer.
Zloza A; Karolina Palucka A; Coussens LM; Gotwals PJ; Headley MB; Jaffee EM; Lund AW; Sharpe AH; Sznol M; Wainwright DA; Wong KK; Bosenberg MW
J Immunother Cancer; 2017 Sep; 5(1):77. PubMed ID: 28923102
[TBL] [Abstract][Full Text] [Related]
8. The humanized mouse: Emerging translational potential.
Morton JJ; Alzofon N; Jimeno A
Mol Carcinog; 2020 Jul; 59(7):830-838. PubMed ID: 32275343
[TBL] [Abstract][Full Text] [Related]
9. Antileukemia and antitumor effects of the graft-versus-host disease: a new immunovirological approach.
Sinkovics JG
Acta Microbiol Immunol Hung; 2010 Dec; 57(4):253-347. PubMed ID: 21183421
[TBL] [Abstract][Full Text] [Related]
10. Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics.
Phoon YP; Lopes JE; Pfannenstiel LW; Marcela Diaz-Montero C; Tian YF; Ernstoff MS; Funchain P; Ko JS; Winquist R; Losey HC; Melenhorst JJ; Gastman BR
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604813
[TBL] [Abstract][Full Text] [Related]
11. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
12. Development of humanized mouse with patient-derived xenografts for cancer immunotherapy studies: A comprehensive review.
Jin KT; Du WL; Lan HR; Liu YY; Mao CS; Du JL; Mou XZ
Cancer Sci; 2021 Jul; 112(7):2592-2606. PubMed ID: 33938090
[TBL] [Abstract][Full Text] [Related]
13. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy.
Wang M; Yao LC; Cheng M; Cai D; Martinek J; Pan CX; Shi W; Ma AH; De Vere White RW; Airhart S; Liu ET; Banchereau J; Brehm MA; Greiner DL; Shultz LD; Palucka K; Keck JG
FASEB J; 2018 Mar; 32(3):1537-1549. PubMed ID: 29146734
[TBL] [Abstract][Full Text] [Related]
14. Fidelity of human ovarian cancer patient-derived xenografts in a partially humanized mouse model for preclinical testing of immunotherapies.
Odunsi A; McGray AJR; Miliotto A; Zhang Y; Wang J; Abiola A; Eppolito C; Huang RY
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33177175
[TBL] [Abstract][Full Text] [Related]
15. Patient-derived xenografts (PDXs) as model systems for human cancer.
Invrea F; Rovito R; Torchiaro E; Petti C; Isella C; Medico E
Curr Opin Biotechnol; 2020 Jun; 63():151-156. PubMed ID: 32070860
[TBL] [Abstract][Full Text] [Related]
16. Humanized Mouse Models for the Preclinical Assessment of Cancer Immunotherapy.
Wege AK
BioDrugs; 2018 Jun; 32(3):245-266. PubMed ID: 29589229
[TBL] [Abstract][Full Text] [Related]
17. Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response.
Zhang F; Wang W; Long Y; Liu H; Cheng J; Guo L; Li R; Meng C; Yu S; Zhao Q; Lu S; Wang L; Wang H; Wen D
Cancer Commun (Lond); 2018 Sep; 38(1):60. PubMed ID: 30257718
[TBL] [Abstract][Full Text] [Related]
18. Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies.
Sanmamed MF; Chester C; Melero I; Kohrt H
Ann Oncol; 2016 Jul; 27(7):1190-8. PubMed ID: 26912558
[TBL] [Abstract][Full Text] [Related]
19. Of Mice, Dogs, Pigs, and Men: Choosing the Appropriate Model for Immuno-Oncology Research.
Overgaard NH; Fan TM; Schachtschneider KM; Principe DR; Schook LB; Jungersen G
ILAR J; 2018 Dec; 59(3):247-262. PubMed ID: 30476148
[TBL] [Abstract][Full Text] [Related]
20. Techniques for the generation of humanized mouse models for immuno-oncology.
Yu CI; Marches F; Wu TC; Martinek J; Palucka K
Methods Enzymol; 2020; 636():351-368. PubMed ID: 32178826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
